Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era
Purpose To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). Methods and Materials We retrospectively reviewed the charts of 107 patients diagnosed with...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2010-07, Vol.77 (4), p.1105-1112 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1112 |
|---|---|
| container_issue | 4 |
| container_start_page | 1105 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 77 |
| creator | Damast, Shari, M.D Ho, Alice Y., M.D Montgomery, Leslie, M.D Fornier, Monica N., M.D Ishill, Nicole, M.S Elkin, Elena, Ph.D Beal, Kathryn, M.D McCormick, Beryl, M.D |
| description | Purpose To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). Methods and Materials We retrospectively reviewed the charts of 107 patients diagnosed with IBC between January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT). Results All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy, and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200 cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment. Median follow-up was 47 months (range, 10–134 months). Locoregional control (LRC) at 3 years and 5 years was 90% and 87%, respectively. Distant metastases–free survival (DMFS) at 3 years and 5 years was 61% and 47%, respectively. Conclusions Excellent locoregional control was observed in this population of IBC patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases–free survival remains a significant therapeutic challenge. |
| doi_str_mv | 10.1016/j.ijrobp.2009.06.042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21436079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301609009559</els_id><sourcerecordid>754881002</sourcerecordid><originalsourceid>FETCH-LOGICAL-c552t-e4e6197f5c9f9df5cad9a99b9f9a46db2fa38c5fb35a9455397ca051dbe500813</originalsourceid><addsrcrecordid>eNqFkt-K1DAUxoso7rr6BiIBEa9mTJqmbW4Ed9zVhYEVZ0Tvwmly6mS2bcYkFecxfGNTOih4szf5-zvfOcl3suw5o0tGWflmv7R775rDMqdULmm5pEX-IDtndSUXXIhvD7Nzyku64Ak-y56EsKeUMlYVj7MzJhNFy_o8-7122nn8bt0AHbkdo3Y9BuJacjO0HfQ9ROeP5NIjhEhWMGj05BNEi0MMZJuOIxry1cYd2UQYDHhDrj3oOAlOA_kMxs6rdE3eg-2OZHNnB3LpujGQtIg7JFv4BQOSKw9Ps0ctdAGfneaL7Mv11Xb1cbG-_XCzerdeaCHyuMACSyarVmjZSpMmMBKkbNIOitI0eQu81qJtuABZCMFlpYEKZhoUlNaMX2QvZ10XolVB24h6p90woI4qZ0X6u0om6vVMHbz7MWKIqrdBY9elat0YVCWKumaU5veTnJdC0LxOZDGT2rsQPLbq4G0P_qgYVZO3aq9mb9XkraKlSt6msBenBGPTo_kXdDIzAa9OAAQNXeuTWzb85fJcVjznk9DbmcP0vT8t-un1mJw11k-PN87eV8n_Arqzg0057_CIYe9Gn7opKKZCrqjaTH04tSGVSUQIyf8Aiz_aLg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733655028</pqid></control><display><type>article</type><title>Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Damast, Shari, M.D ; Ho, Alice Y., M.D ; Montgomery, Leslie, M.D ; Fornier, Monica N., M.D ; Ishill, Nicole, M.S ; Elkin, Elena, Ph.D ; Beal, Kathryn, M.D ; McCormick, Beryl, M.D</creator><creatorcontrib>Damast, Shari, M.D ; Ho, Alice Y., M.D ; Montgomery, Leslie, M.D ; Fornier, Monica N., M.D ; Ishill, Nicole, M.S ; Elkin, Elena, Ph.D ; Beal, Kathryn, M.D ; McCormick, Beryl, M.D</creatorcontrib><description>Purpose To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). Methods and Materials We retrospectively reviewed the charts of 107 patients diagnosed with IBC between January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT). Results All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy, and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200 cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment. Median follow-up was 47 months (range, 10–134 months). Locoregional control (LRC) at 3 years and 5 years was 90% and 87%, respectively. Distant metastases–free survival (DMFS) at 3 years and 5 years was 61% and 47%, respectively. Conclusions Excellent locoregional control was observed in this population of IBC patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases–free survival remains a significant therapeutic challenge.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2009.06.042</identifier><identifier>PMID: 19879068</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject><![CDATA[Adenocarcinoma - drug therapy ; Adenocarcinoma - radiotherapy ; Adenocarcinoma - surgery ; Adjuvants ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; ANTINEOPLASTIC DRUGS ; Biological and medical sciences ; BODY ; Breast Neoplasms - drug therapy ; Breast Neoplasms - radiotherapy ; Breast Neoplasms - surgery ; Capecitabine ; Carboplatin - administration & dosage ; Combined modality treatment ; Cyclophosphamide - administration & dosage ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease-Free Survival ; DISEASES ; Dose Fractionation ; Doxorubicin - administration & dosage ; Drug Administration Schedule ; DRUGS ; Epirubicin - administration & dosage ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; FRACTIONATED IRRADIATION ; GLANDS ; Gynecology. Andrology. Obstetrics ; Hematology, Oncology and Palliative Medicine ; Humans ; INFLAMMATION ; Inflammatory breast cancer ; IRRADIATION ; Mammary gland diseases ; MAMMARY GLANDS ; Mastectomy, Modified Radical ; Medical sciences ; MEDICINE ; Middle Aged ; Neoadjuvant Therapy - methods ; NEOPLASMS ; NUCLEAR MEDICINE ; ORGANS ; Paclitaxel - administration & dosage ; PATHOLOGICAL CHANGES ; Radiation ; Radiodermatitis - etiology ; RADIOLOGY ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy, Adjuvant - adverse effects ; Retrospective Studies ; SKIN ; Standard fractionation ; SYMPTOMS ; Taxanes ; THERAPY ; Tumors]]></subject><ispartof>International journal of radiation oncology, biology, physics, 2010-07, Vol.77 (4), p.1105-1112</ispartof><rights>Elsevier Inc.</rights><rights>2010 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c552t-e4e6197f5c9f9df5cad9a99b9f9a46db2fa38c5fb35a9455397ca051dbe500813</citedby><cites>FETCH-LOGICAL-c552t-e4e6197f5c9f9df5cad9a99b9f9a46db2fa38c5fb35a9455397ca051dbe500813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2009.06.042$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22973232$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19879068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21436079$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Damast, Shari, M.D</creatorcontrib><creatorcontrib>Ho, Alice Y., M.D</creatorcontrib><creatorcontrib>Montgomery, Leslie, M.D</creatorcontrib><creatorcontrib>Fornier, Monica N., M.D</creatorcontrib><creatorcontrib>Ishill, Nicole, M.S</creatorcontrib><creatorcontrib>Elkin, Elena, Ph.D</creatorcontrib><creatorcontrib>Beal, Kathryn, M.D</creatorcontrib><creatorcontrib>McCormick, Beryl, M.D</creatorcontrib><title>Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). Methods and Materials We retrospectively reviewed the charts of 107 patients diagnosed with IBC between January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT). Results All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy, and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200 cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment. Median follow-up was 47 months (range, 10–134 months). Locoregional control (LRC) at 3 years and 5 years was 90% and 87%, respectively. Distant metastases–free survival (DMFS) at 3 years and 5 years was 61% and 47%, respectively. Conclusions Excellent locoregional control was observed in this population of IBC patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases–free survival remains a significant therapeutic challenge.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - surgery</subject><subject>Adjuvants</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>ANTINEOPLASTIC DRUGS</subject><subject>Biological and medical sciences</subject><subject>BODY</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - radiotherapy</subject><subject>Breast Neoplasms - surgery</subject><subject>Capecitabine</subject><subject>Carboplatin - administration & dosage</subject><subject>Combined modality treatment</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease-Free Survival</subject><subject>DISEASES</subject><subject>Dose Fractionation</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>DRUGS</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>FRACTIONATED IRRADIATION</subject><subject>GLANDS</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>INFLAMMATION</subject><subject>Inflammatory breast cancer</subject><subject>IRRADIATION</subject><subject>Mammary gland diseases</subject><subject>MAMMARY GLANDS</subject><subject>Mastectomy, Modified Radical</subject><subject>Medical sciences</subject><subject>MEDICINE</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy - methods</subject><subject>NEOPLASMS</subject><subject>NUCLEAR MEDICINE</subject><subject>ORGANS</subject><subject>Paclitaxel - administration & dosage</subject><subject>PATHOLOGICAL CHANGES</subject><subject>Radiation</subject><subject>Radiodermatitis - etiology</subject><subject>RADIOLOGY</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy, Adjuvant - adverse effects</subject><subject>Retrospective Studies</subject><subject>SKIN</subject><subject>Standard fractionation</subject><subject>SYMPTOMS</subject><subject>Taxanes</subject><subject>THERAPY</subject><subject>Tumors</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt-K1DAUxoso7rr6BiIBEa9mTJqmbW4Ed9zVhYEVZ0Tvwmly6mS2bcYkFecxfGNTOih4szf5-zvfOcl3suw5o0tGWflmv7R775rDMqdULmm5pEX-IDtndSUXXIhvD7Nzyku64Ak-y56EsKeUMlYVj7MzJhNFy_o8-7122nn8bt0AHbkdo3Y9BuJacjO0HfQ9ROeP5NIjhEhWMGj05BNEi0MMZJuOIxry1cYd2UQYDHhDrj3oOAlOA_kMxs6rdE3eg-2OZHNnB3LpujGQtIg7JFv4BQOSKw9Ps0ctdAGfneaL7Mv11Xb1cbG-_XCzerdeaCHyuMACSyarVmjZSpMmMBKkbNIOitI0eQu81qJtuABZCMFlpYEKZhoUlNaMX2QvZ10XolVB24h6p90woI4qZ0X6u0om6vVMHbz7MWKIqrdBY9elat0YVCWKumaU5veTnJdC0LxOZDGT2rsQPLbq4G0P_qgYVZO3aq9mb9XkraKlSt6msBenBGPTo_kXdDIzAa9OAAQNXeuTWzb85fJcVjznk9DbmcP0vT8t-un1mJw11k-PN87eV8n_Arqzg0057_CIYe9Gn7opKKZCrqjaTH04tSGVSUQIyf8Aiz_aLg</recordid><startdate>20100715</startdate><enddate>20100715</enddate><creator>Damast, Shari, M.D</creator><creator>Ho, Alice Y., M.D</creator><creator>Montgomery, Leslie, M.D</creator><creator>Fornier, Monica N., M.D</creator><creator>Ishill, Nicole, M.S</creator><creator>Elkin, Elena, Ph.D</creator><creator>Beal, Kathryn, M.D</creator><creator>McCormick, Beryl, M.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20100715</creationdate><title>Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era</title><author>Damast, Shari, M.D ; Ho, Alice Y., M.D ; Montgomery, Leslie, M.D ; Fornier, Monica N., M.D ; Ishill, Nicole, M.S ; Elkin, Elena, Ph.D ; Beal, Kathryn, M.D ; McCormick, Beryl, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c552t-e4e6197f5c9f9df5cad9a99b9f9a46db2fa38c5fb35a9455397ca051dbe500813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - surgery</topic><topic>Adjuvants</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>ANTINEOPLASTIC DRUGS</topic><topic>Biological and medical sciences</topic><topic>BODY</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - radiotherapy</topic><topic>Breast Neoplasms - surgery</topic><topic>Capecitabine</topic><topic>Carboplatin - administration & dosage</topic><topic>Combined modality treatment</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease-Free Survival</topic><topic>DISEASES</topic><topic>Dose Fractionation</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>DRUGS</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>FRACTIONATED IRRADIATION</topic><topic>GLANDS</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>INFLAMMATION</topic><topic>Inflammatory breast cancer</topic><topic>IRRADIATION</topic><topic>Mammary gland diseases</topic><topic>MAMMARY GLANDS</topic><topic>Mastectomy, Modified Radical</topic><topic>Medical sciences</topic><topic>MEDICINE</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy - methods</topic><topic>NEOPLASMS</topic><topic>NUCLEAR MEDICINE</topic><topic>ORGANS</topic><topic>Paclitaxel - administration & dosage</topic><topic>PATHOLOGICAL CHANGES</topic><topic>Radiation</topic><topic>Radiodermatitis - etiology</topic><topic>RADIOLOGY</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy, Adjuvant - adverse effects</topic><topic>Retrospective Studies</topic><topic>SKIN</topic><topic>Standard fractionation</topic><topic>SYMPTOMS</topic><topic>Taxanes</topic><topic>THERAPY</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Damast, Shari, M.D</creatorcontrib><creatorcontrib>Ho, Alice Y., M.D</creatorcontrib><creatorcontrib>Montgomery, Leslie, M.D</creatorcontrib><creatorcontrib>Fornier, Monica N., M.D</creatorcontrib><creatorcontrib>Ishill, Nicole, M.S</creatorcontrib><creatorcontrib>Elkin, Elena, Ph.D</creatorcontrib><creatorcontrib>Beal, Kathryn, M.D</creatorcontrib><creatorcontrib>McCormick, Beryl, M.D</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Damast, Shari, M.D</au><au>Ho, Alice Y., M.D</au><au>Montgomery, Leslie, M.D</au><au>Fornier, Monica N., M.D</au><au>Ishill, Nicole, M.S</au><au>Elkin, Elena, Ph.D</au><au>Beal, Kathryn, M.D</au><au>McCormick, Beryl, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2010-07-15</date><risdate>2010</risdate><volume>77</volume><issue>4</issue><spage>1105</spage><epage>1112</epage><pages>1105-1112</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose To assess locoregional outcomes of inflammatory breast cancer (IBC) patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy (CMT). Methods and Materials We retrospectively reviewed the charts of 107 patients diagnosed with IBC between January 1995 and March 2006 who presented to our department for adjuvant radiation therapy (RT). Results All patients received chemotherapy (95% anthracycline and 95% taxane), modified radical mastectomy, and RT to the chest wall and regional lymphatics using standard fractionation to 50 Gy and daily skin bolus. The RT to the chest wall was delivered via electrons (55%) or photons (45%) in daily fractions of 180 cGy (73%) or 200 cGy (27%). Scar boost was performed in 11%. A majority (84%) of patients completed the prescribed treatment. Median follow-up was 47 months (range, 10–134 months). Locoregional control (LRC) at 3 years and 5 years was 90% and 87%, respectively. Distant metastases–free survival (DMFS) at 3 years and 5 years was 61% and 47%, respectively. Conclusions Excellent locoregional control was observed in this population of IBC patients who received standard fractionation radiation with daily skin bolus and taxanes as part of combined-modality therapy. Distant metastases–free survival remains a significant therapeutic challenge.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19879068</pmid><doi>10.1016/j.ijrobp.2009.06.042</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2010-07, Vol.77 (4), p.1105-1112 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_21436079 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - radiotherapy Adenocarcinoma - surgery Adjuvants Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use ANTINEOPLASTIC DRUGS Biological and medical sciences BODY Breast Neoplasms - drug therapy Breast Neoplasms - radiotherapy Breast Neoplasms - surgery Capecitabine Carboplatin - administration & dosage Combined modality treatment Cyclophosphamide - administration & dosage Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease-Free Survival DISEASES Dose Fractionation Doxorubicin - administration & dosage Drug Administration Schedule DRUGS Epirubicin - administration & dosage Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives FRACTIONATED IRRADIATION GLANDS Gynecology. Andrology. Obstetrics Hematology, Oncology and Palliative Medicine Humans INFLAMMATION Inflammatory breast cancer IRRADIATION Mammary gland diseases MAMMARY GLANDS Mastectomy, Modified Radical Medical sciences MEDICINE Middle Aged Neoadjuvant Therapy - methods NEOPLASMS NUCLEAR MEDICINE ORGANS Paclitaxel - administration & dosage PATHOLOGICAL CHANGES Radiation Radiodermatitis - etiology RADIOLOGY RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy, Adjuvant - adverse effects Retrospective Studies SKIN Standard fractionation SYMPTOMS Taxanes THERAPY Tumors |
| title | Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T20%3A02%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Locoregional%20Outcomes%20of%20Inflammatory%20Breast%20Cancer%20Patients%20Treated%20With%20Standard%20Fractionation%20Radiation%20and%20Daily%20Skin%20Bolus%20in%20the%20Taxane%20Era&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Damast,%20Shari,%20M.D&rft.date=2010-07-15&rft.volume=77&rft.issue=4&rft.spage=1105&rft.epage=1112&rft.pages=1105-1112&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2009.06.042&rft_dat=%3Cproquest_osti_%3E754881002%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733655028&rft_id=info:pmid/19879068&rft_els_id=S0360301609009559&rfr_iscdi=true |